Ivax Secures Approval for Generic Version of Cancer Drug
WASHINGTON-Ivax Corp. received federal approval for its generic version of the cancer drug Taxol, making possible a less-expensive version of the blockbuster drug. According to the company, distribution of paclitaxel will begin in a matter of weeks. The drug, widely used to treat breast and ovarian cancers, won tentative approval in August. However, because of pending litigation and patent questions, was unable to receive approval. A spokesperson for the company would not comment on the price but stated that generic versions of brand-name drugs typically cost 30% less. Taxol costs about $7,000 for each course of treatment, but the amount varies depending upon the condition. For more information visit www.ivax.com.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
